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Abstract
 
Lymphoproliferative (lpr) mice, which lack functional Fas receptor expression and develop
autoimmune lymphoproliferative disease, have an accumulation of T cell receptor-
 
  
 
 
 
CD4
 
 
 
CD8
 
  
 
(double negative T cells [DNTC]) in the periphery. The function of the
accumulating DNTC is not clear. In this study we demonstrate that B6/lpr DNTC can dose
dependently kill syngeneic CD8
 
  
 
and CD4
 
  
 
T cells from wild-type B6 mice through Fas/Fas
ligand interactions in vitro. We also demonstrate that B6/lpr DNTC that are activated and ex-
pand in vivo are able to specifically down-regulate allogeneic immune responses mediated by
syngeneic Fas
 
 
 
CD4
 
  
 
and CD8
 
  
 
T cells in vivo. B6/lpr DNTC that have been preactivated in
vivo by infusion of either class I– (bm1) or class II– (bm12) mismatched allogeneic lympho-
cytes are able to specifically enhance the survival of bm1 or bm12, but not third-party skin
allografts when adoptively transferred into naive B6
 
 
 
/
 
  
 
mice. These findings clearly demon-
strate that B6/lpr DNTC have a potent immune regulatory function in vitro and in vivo
 
.
 
 They
also provide new insights into the mechanisms involved in the development of autoimmune
disease in lpr mice.
Key words: autoimmune • transplantation • immune tolerance • suppressor T lymphocytes • 
Fas ligand
 
Introduction
 
Compelling evidence indicate that regulatory T cells play
an important role in the maintenance of immune tolerance
to self- and foreign antigens (1–3). Various subsets of T
lymphocytes have been isolated from peripheral lymphoid
organs in mice and humans that have the ability to down-
regulate the proliferation of autoimmune effector cells (4–
6). CD4
 
 
 
CD25
 
  
 
T cells are the most extensively studied
regulatory T cells. Eliminating CD4
 
 
 
CD25
 
  
 
T cells from
the periphery of mice leads to the development of systemic
autoimmune diseases and adding these T cells back amelio-
rates experimentally induced autoimmune symptoms (7).
Other regulatory T cells, including CD4
 
 
 
CD45Rb
 
low
 
 (1),
CD4
 
 
 
DX5
 
  
 
T cells (8), CD8
 
  
 
T cells (9), 
 
  
 
-TCR
 
  
 
cells
(10), and 
 
  
 
-TCR
 
  
 
CD3
 
 
 
CD4
 
 
 
CD8
 
  
 
double negative T
cells (DNTC; references 11 and 12) have also been demon-
strated in various models to have a potent role in down-
regulating immune responses.
Lymphoproliferative (lpr) mice, which have a mutation
in the gene responsible for the production of functional
Fas molecules (13), develop systemic autoimmune disease
concurrent with an accumulation of mature peripheral
DNTC (14, 15). The development of autoimmune dis-
ease has been suggested to be caused by autoreactive T
cells in the periphery from either incomplete negative se-
lection in the thymus (16) or as more recent studies indi-
cate, impaired peripheral deletion (17). In particular, T
cells that are reactive to mouse endogenous superantigens
are deleted in the thymus of Fas-null mice, but peripheral
deletion in response to bacterial superantigen is impaired
in the same mice (17). These data suggest that Fas muta-
tion leads to the breakdown of peripheral tolerance.
However, the mechanism leading to the impaired periph-
eral deletion remains unknown. Furthermore, the func-
tion of the accumulating DNTC in the periphery of lpr
mice is still unclear.
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We and others have demonstrated that DNTC and
clones from transgenic mice can down-regulate immune
responses by killing activated alloreactive CD8
 
  
 
T cells that
express functional Fas receptors but not CD8
 
  
 
T cells from
lpr mice that express nonfunctional Fas (11, 12). Recently,
it was found that DNTC from normal mice can also down-
regulate allogeneic immune responses in vitro and in vivo
(11, 18). These data indicate that peripheral DNTC have a
regulatory function in a variety of models. Because DNTC
from lpr mice express similar cell surface markers to the
regulatory DNTC clones (11, 19) and can kill syngeneic
Fas
 
  
 
thymocytes in vitro when stimulated by PMA and
ionomycin (20)
 
,
 
 the accumulating DNTC in lpr mice may
have a regulatory function. The goal of this study was to
characterize the function of lpr DNTC. The results shown
here demonstrate that lpr DNTC can down-regulate allo-
geneic immune responses mediated by syngeneic wild-type
but not lpr CD4
 
  
 
and CD8
 
  
 
T cells both in vitro and in
vivo
 
.
 
 The inability of DNTC to kill activated lpr CD4
 
 
 
and CD8
 
  
 
T cells may contribute to the development of
autoimmune disease in lpr mice.
 
Materials and Methods
 
Mice.
 
C57BL/6 (B6
 
 
 
/
 
 
 
), B6.MRL-Fas
 
lpr 
 
(B6/lpr), B6Smn.
C3H-Fasl
 
gld
 
 (B6/gld), B6.C-H2
 
bm1
 
/By (bm1), B6.C-H2
 
bm12
 
/By
(bm12), BALB/c-H-2-dm2 (dm2, a BALB/c L
 
d 
 
loss mutant),
and BALB/c mice were purchased from Jackson Immuno-
Research Laboratories. All mice were maintained in the Univer-
sity Health Network (UNH; University of Toronto, Toronto,
Canada) animal colonies. (B6Xdm2)
 
F1 
 
mice and the B6-P14
(P14) mice possessing a transgenic TCR specific for the lympho-
cytic choriomeningitis virus gp33 peptide (21) were bred in
UHN animal facilities.
 
Isolation of DNTC.
 
Spleen and lymph node cells of B6/lpr
mice were depleted of red blood cells and then passed through a
nylon wool column to enrich the T cell population. The cells
were then treated with depletion antibodies specific for murine
CD4 (RL172, rat IgM; reference 22) and CD8 (3.168.8, rat IgM;
reference 22) and rabbit complement (Cedarlane) to deplete
CD4
 
  
 
and CD8
 
  
 
T cells.
 
Generation of Effector and Target T Cells for Killing Assays.
 
Al-
loreactive H-2
 
d
 
–specific DNTC CD8
 
  
 
and CD4
 
  
 
T cells were
generated by incubating each purified cell type with irradiated (20
Gy) BALB/c splenocytes. gp33-specific CD8
 
  
 
T cells were gen-
erated by incubating spleen cells from P14 TCR transgenic mice
with gp33 (23). The cells were cultured in 
 
 
 
-MEM media sup-
plemented with 10% FCS and 50 U rIL-2. DNTC cultures also
received 30 U rIL-4.
 
Killing Assays.
 
Primary activated B6/lpr or B6/gld DNTC
were used as effector cells and plated in serial dilutions in a
round-bottom 96-well plate. Target cells labeled with 5 
 
 
 
Ci/ml
[
 
3
 
H]TdR at 37
 
 
 
C for 18 h were washed three times and added in
equal portions to each well. Each cell culture was also given 50 U
rIL-2, 30 U rIL-4, and irradiated (20 Gy) allogeneic stimulator
cells or peptide depending on the experiment. After coculture
with effector cells at 37
 
 
 
C for 18 h, the cells were harvested and
counted using a TOP COUNT™
 
 
 
cell harvester and plate reader
(Packard Instrument Co.). Specific cell killing was calculated us-
ing this equation: % Specific killing 
 
 
 
 
 
(SE)/S 
 
  
 
100, where E
(experimental) is cpm of retained DNA in the presence of effec-
 
tor cells and S (spontaneous) is cpm of retained DNA in the ab-
sence of effector cells.
 
Cell Surface Marker Staining and Blocking.
 
B6/lpr spleen and lymph
node cells were harvested 7 d after donor lymphocyte infusion
(DLI) treatment and stained with fluorescence-conjugated mono-
clonal antibodies specifically recognizing CD3, CD4, and CD8
(BD Biosciences). Data were acquired and analyzed on an Epics
XL-MCL flow cytometer (Coulter Corp.). Fas ligand (FasL) was
blocked using recombinant mouse Fas-Fc chimera/TNFRSF6
(R&D Systems).
 
DLI, Adoptive Transfer of Lymphocytes, and Skin Grafting.
 
B6/
lpr mice were injected with a mixture of 4.0 
 
  
 
10
 
7 
 
spleen and
lymph node cells from either bm1 or bm12 mice. Spleen and
lymph node cells from the B6/lpr mice were harvested 7 d after
the infusion of allogeneic cells. Naive B6
 
 
 
/
 
  
 
mice intravenously
received either 4.0 
 
  
 
10
 
7 
 
full spleen and lymph node cells or
DNTC isolated from DLI-treated lpr mice. 1 d later, all B6
 
 
 
/
 
 
 
recipient mice were given skin grafts from either bm1 or bm12
mice and a third-party skin graft (BALB/c or [B6Xdm2]
 
F1
 
) as
previously reported (24). Survival of the skin grafts was moni-
tored and scored until rejection.
 
Statistics.
 
All skin grafting survival data were analyzed using
the Student’s 
 
t
 
 test.
 
Results
 
B6/lpr DNTC Kill Activated Syngeneic CD8
 
  
 
T Cells
through the Fas/FasL Pathway.
 
We and others have dem-
onstrated that DNTC and clones derived from normal and
transgenic mice can kill activated syngeneic CD8
 
  
 
target
cells through the Fas/FasL pathway (11, 12). Furthermore,
mitogen-activated lpr DNTC can kill syngeneic Fas
 
  
 
thy-
mocytes (20). These findings suggest that lpr DNTC also
have a regulatory role but are unable to execute their
function due to the lack of functional Fas expression on
their target cells. To test this hypothesis, B6/lpr DNTC
were isolated from spleen and lymph nodes, allogeneically
stimulated, and used as putative regulatory cells. CD8
 
  
 
T
cells from B6
 
 
 
/
 
  
 
(Fas
 
 
 
/
 
 
 
) and B6/lpr (Fas-mutant) mice
were similarly activated and used as targets in a JAM cyto-
toxicity assay (25). As shown in Fig. 1 A, B6/lpr DNTC
killed B6
 
 
 
/
 
  
 
(Fas
 
 
 
/
 
 
 
) CD8
 
  
 
T cells much more effectively
than the B6/lpr (Fas-mutant) CD8
 
  
 
T cells. This result is
consistent with the data obtained from non-lpr DNTC
and indicates that allogeneically activated lpr DNTC can
kill activated syngeneic CD8
 
  
 
T cells from wild-type but
not Fas-mutant lpr mice, which suggests that Fas–FasL in-
teraction is an important mechanism in B6/lpr DNTC-
mediated killing.
Autoimmune-prone gld mice express FasL in a nonfunc-
tional conformation that is not able to ligate Fas on target
cells (13, 14). As seen in lpr mice, DNTC also accumulate
in gld mice concomitant with the development of autoim-
mune disease symptoms (13, 14). To determine if the ex-
pression of FasL on DNTC is important for the killing of
CD8
 
  
 
T cells, DNTC from B6/gld (FasL-mutant) mice
were purified and their ability to kill activated syngeneic
Fas
 
 
 
CD8
 
  
 
T cells was compared with DNTC from B6/lpr
(FasL
 
 
 
/
 
 
 
) mice. As shown in Fig. 1 B, the cytotoxicity to 
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activated syngeneic Fas
 
 
 
CD8
 
  
 
T cells mediated by B6/gld
DNTC was significantly reduced compared with that of
B6/lpr DNTC. This result indicates that the expression of
functional FasL on DNTC enhances the ability of DNTC
to kill CD8
 
  
 
T cell targets.
To further determine the specific contribution of FasL
expression on lpr DNTC-mediated killing of syngeneic T
cells, FasL on lpr DNTC was blocked with various con-
centrations of Fas–Fc fusion protein before coincubation
with a fixed number of syngeneic Fas
 
 
 
CD8
 
  
 
T cells. The
ability of lpr DNTC to kill syngeneic Fas
 
 
 
CD8
 
  
 
T cells
was significantly inhibited when FasL was blocked on lpr
DNTC by increasing concentrations of Fas–Fc fusion pro-
tein (Fig. 1 C). Taken together, these data demonstrate that
lpr DNTC are able to down-regulate allogeneic immune
responses mediated by syngeneic CD8
 
  
 
T cells and the ex-
pression of functional FasL on DNTC and Fas on target
CD8
 
  
 
T cells is important for lpr DNTC-mediated killing.
 
In Vitro–activated B6/lpr DNTC Are Cytotoxic to B6
 
 
 
/
 
 
 
CD4
 
  
 
and CD8
 
  
 
T Cells That Are Activated by a Different
Antigen.
 
To further characterize the ability of lpr DNTC
to regulate wild-type T cells, we first assessed the ability of
H-2
 
d
 
–specific B6/lpr DNTC to kill activated syngeneic
H-2
 
d
 
–specific B6
 
 
 
/
 
  
 
CD4
 
 
 
, in addition to CD8 , T cells. Fig.
2 A shows that B6/lpr DNTC could dose dependently kill
both activated syngeneic H-2d–specific CD8  and CD4  T
cells from normal B6 /  mice. Next, we addressed the
question of whether the killing of syngeneic T cells medi-
ated by lpr DNTC was antigen specific. Activated H-2d–
specific B6/lpr DNTC were tested for their ability to kill
syngeneic T cells that are activated by either the same or a
different antigen. Specifically, CD8  T cells from B6 / 
mice were activated against H-2d as described in Materials
and Methods, or B6 transgenic P14 CD8  T cells were
stimulated with p33 peptide to create CD8  T cell targets
that carried TCR of different specificity from the B6/lpr
DNTC. The ability of H-2d–specific B6/lpr DNTC to kill
each cell type was compared. Fig. 2 B shows that H-2d–
specific B6/lpr DNTC effectively killed both p33- and
H-2d–specific CD8  T cells. Together, these data indicate
that lpr DNTC that were activated in vitro with allogeneic
splenocytes can kill both activated syngeneic CD4  and
CD8  T cells, and the cytotoxicity to syngeneic CD8  T
cells is not antigen specific in vitro.
Infusion of Allogeneic Lymphocytes Leads to Expansion of
B6/lpr DNTC. DLI has been shown to enhance organ
allograft survival in mice (24) and humans (26). Recently,
we have demonstrated that pretransplant DLI induces the
activation and expansion of recipient DNTC and the pro-
longation of allograft (18) and xenograft survival (unpub-
lished data), and that adoptive transfer of activated DNTC
clones can enhance donor-specific but not third-party skin
graft survival (11).
To investigate the function of B6/lpr DNTC in vivo,
we first studied whether B6/lpr DNTC can be activated
and expand in vivo after the infusion of allogeneic lympho-
cytes. B6/lpr mice were given a DLI of bm1 (single class
I–mismatched) spleen and lymph node cells. The recipient
mice were killed 7 d later and the percentages of CD8 ,
CD4 , and DNTC in the lymph nodes and spleen were
analyzed by flow cytometry. 1 wk after DLI there was no
significant change in the percentage of CD8  T cells and a
significantly reduced proportion of CD4  T cells in the
spleen (P   0.05) but not in the lymph nodes compared
with age-matched B6/lpr non-DLI–treated controls. Inter-
estingly, the percentage of DNTC in both the lymph nodes
(Fig. 3 A) and spleen (Fig. 3 B) of DLI-treated B6/lpr mice
was significantly increased compared with age-matched
Figure 1. Lpr DNTC kill target cells through the Fas/FasL pathway.
(A) H-2d–specific B6/lpr DNTC effectors were prepared as described in
Materials and Methods and cocultured with primary activated CD8  T
cells from either B6 /  (light bars), or B6/lpr (dark bars) mice. The per-
cent-specific lysis of target cells was calculated. The data are expressed as
mean percent killing of three replicate cultures. The experiment was
repeated twice and similar results were obtained. (B) Activated B6
Fas CD8  T cells cocultured with DNTC isolated from either B6/lpr
(light bars) or B6/gld (dark bars) mice. The percent-specific lysis of target
cells was calculated. The data are expressed as mean percent killing of
three replicate cultures. (C) 5   104/well of activated B6/lpr DNTC
were incubated with Fas–Fc fusion protein in the indicated concentra-
tions for 20 min and then cocultured with 104 primary activated B6 / 
CD8  T cell targets. The mean percent inhibition of specific lysis of B6 / 
CD8 target cells compared with killing detected in the absence of Fas–Fc
is shown. The data represent three replicate cultures. The experiment was
repeated twice and representative data are shown.264 The Immune Regulatory Function of lpr DN T Cells
untreated controls (P   0.04 and P   0.02, respectively).
This data indicates that single MHC class I locus–mis-
matched DLI can promote the activation and proliferation
of lpr DNTC in vivo.
Adoptive Transfer of In Vivo–activated B6/lpr DNTC En-
hances Specific Skin Allograft Survival. Our finding that in
vitro–activated lpr DNTC can kill both CD4  and CD8 
T cells suggests that DNTC might be able to inhibit im-
mune responses in vivo. To study whether the in vivo–acti-
vated lpr DNTC could enhance donor-specific skin graft
survival, the spleen and lymph node cells were collected
from B6/lpr mice 1 wk after the infusion of bm1 lympho-
cytes. Naive B6 /  mice were used as skin graft recipients
and divided into two groups. One group was infused with
a mixture of DLI-treated B6/lpr spleen and lymph node
cells, and the other was left untreated as a control. 1 d later,
both groups of mice were given tail skin grafts from bm1
(antigen-specific) and BALB/c (third-party) donors. Skin
graft survival was monitored as previously described (11).
Fig. 4 A shows that the mean survival time (MST) of bm1
skin grafts was significantly enhanced in mice that received
B6/lpr lymphocytes that were preactivated by bm1 anti-
gens (MST   28.8 d, n   8) when compared with that of
the control group (MST   15.7 d, n   6, P   0.046). All
third-party BALB/c skin grafts were rejected within the
normal time course by both groups, indicating that the en-
hancement of skin graft survival was donor specific.
To further determine the specific contribution of B6/lpr
DNTC in enhancing skin allograft survival, DNTC were
isolated from the peripheral lymphocytes of bm1 DLI-
treated B6/lpr mice. The in vivo–activated bm1-specific
B6/lpr DNTC were adoptively transferred into naive B6 / 
mice 1 d before transplantation. Each recipient B6 / 
mouse was then given skin grafts from bm1 (donor-spe-
cific) and BALB/c (third-party) mice. Graft survival was
compared with the B6 /  mice that were given the same
skin grafts without pretransplant infusion of B6/lpr
DNTC. As shown in Fig. 4 B, the MST of bm1 skin grafts
was significantly prolonged in the mice that received in
vivo–activated bm1-specific DNTC when compared with
the controls (MST   47.5 d, n   10 vs. MST 15.7 d, n  
6, P   0.017). In contrast, both treatment groups rejected
all third-party BALB/c skin grafts within 2 wk. These data
demonstrate that the infusion of in vivo–activated B6/lpr
DNTC can significantly enhance donor-specific bm1 skin
allograft survival.
To test whether B6/lpr DNTC could also enhance the
survival of MHC class II–mismatched skin grafts, B6/lpr
mice were infused with bm12 (class II–mismatched) spleen
Figure 2. In vitro–activated B6/lpr DNTC are cytotoxic to B6 / 
CD4  and CD8  T cells that are activated by a different antigen. (A)
DNTC were purified from the spleens of B6/lpr mice and cultured for 3.5 d
in the presence of irradiated BALB/c splenocytes, rIL-2 and rIL-4, and
used as effector cells. In vitro–activated H-2d–specific B6 /  CD4  (dark
bars) and CD8  (light bars) T cells were used as targets. After 18 h of co-
culture, cells were harvested and counted, and the percent-specific killing
was calculated. The data are expressed as mean percent killing of three
replicate cultures. The experiment was repeated three times and represen-
tative data is shown. (B) Splenic CD8  T cells from B6 mice or B6 anti–
lymphocytic choriomeningitis virus-gp33 were activated in vitro with
either irradiated BALB/c spleen cells or gp33 peptide as described previ-
ously (21, 23). H-2d–specific B6/lpr DNTC were stimulated indepen-
dently by BALB/c spleen cells and cocultured with either H-2d–specific
B6 /  CD8  T cells (light bars), or p33-specific B6 CD8  T cells (dark
bars). The percent-specific killing of each target cell culture was deter-
mined. The data are expressed as mean percent killing of three replicate
cultures. The experiment was repeated three times and representative data
is shown.
Figure 3. Increase of DNTC in the lymph nodes and spleen of B6/lpr
mice after infusion of bm1 cells. B6/lpr mice were injected intravenously
with 4   107 bm1 lymphocytes. 7 d later, (A) lymph node and (B) spleen
lymphocytes were harvested from bm1 cell-injected (dark bars) and age-
matched control (light bars) mice. The percentage of CD3 CD4 CD8 ,
CD3 CD4 CD8 , and CD3 CD4 CD8  cell populations were ana-
lyzed by flow cytometry. The DNTC population was significantly in-
creased in both the spleen (n   5) and lymph nodes (n   4) of DLI-
treated mice when compared with age-matched nontreated control mice
(n   5; spleen, P   0.02 and lymph node, P   0.04).265 Ford et al. Brief Definitive Report
and lymph node cells. The in vivo–activated bm12-specific
B6/lpr DNTC were isolated and transferred into naive
B6 /  mice 1 d before transplantation or left untreated as a
control. All B6 /  recipient mice then received skin grafts
from both bm12 mice (antigen-specific) and (B6xdm2)F1
(third-party) donors. Fig. 4 C shows that the mice that re-
ceived bm12-specific B6/lpr DNTC had significant en-
hancement of bm12 skin graft survival (MST   29.7, n  
7) when compared with control mice that did not receive
any B6/lpr DNTC (MST   8.2, n   5, P   0.0012).
Third-party allogeneic (B6xdm2)F1 skin grafts were re-
jected at the same pace by both groups of recipients. These
results demonstrate that in vivo–activated B6/lpr DNTC
can also specifically enhance the survival of MHC class II–
mismatched skin allograft survival. Together, these find-
ings confirm and extend the results obtained from non-lpr
mice (11, 24) and demonstrate that in vivo–activated B6/
lpr DNTC can inhibit the immune response of syngeneic
T cells toward MHC class I and II alloantigens in vivo,
and prolong skin graft survival in an antigen-specific
manner.
Discussion
The accumulation of TCR-    DNTC cells in the pe-
riphery of autoimmune lpr mice and patients has been ob-
served for many years. However, the function and mecha-
nism of these DNTC has remained elusive. Previous
studies have shown that mature peripheral DNTC from
transgenic (11, 12) and normal mice (11, 18) are able to
down-regulate alloimmune responses mediated by synge-
neic CD4  and CD8  T cells in vitro through the Fas–FasL
pathway. Furthermore, several studies indicate that lpr
DNTC may have a regulatory function. Watenabe et al.
(15) demonstrated that the DNTC population in lpr mice
could kill allogeneic tumor target cells through a FasL-
dependent mechanism. Benihoud et al. (20) showed that lpr
DNTC can kill syngeneic Fas-expressing T cells in vitro af-
ter stimulation with PMA and ionomycin. The results pre-
sented in this paper demonstrate for the first time that the
DNTC that accumulate in autoimmune-prone lpr mice
possess a potent ability to down-regulate allogeneic im-
mune responses mediated by syngeneic CD4  and CD8  T
cells from wild-type mice both in vitro and in vivo.
It is well known that regulatory T cells play an important
role in preventing autoimmune diseases (4–6). Various
studies have shown that autoimmune diseases develop be-
cause of a lack or a malfunction of regulatory cells (1, 2, 7,
8). In lpr mice, the number of DNTC is much higher than
what is seen in normal mice, yet the animals develop au-
toimmune disease. Here we demonstrate that although
DNTC from autoimmune-prone gld mice that lack func-
tional FasL molecules cannot kill activated syngeneic Fas 
CD8  T cells, lpr DNTC are able to kill both activated
syngeneic CD4  and CD8  T cells that express functional
Fas receptors. These results indicate that the regulatory
function of DNTC in lpr mice is retained. Thus, we specu-
late that DNTC might accumulate partly as a failed attempt
to suppress peripheral autoimmune T cells, and partly as a
result of their own inability to undergo Fas-mediated acti-
vation-induced apoptosis. Because lpr DNTC-mediated
suppression depends on interactions between FasL on the
DNTC and Fas expressed on target cells, autoimmune dis-
ease may develop in lpr mice because the mutation of Fas
on autoimmune CD4  and CD8  T cells renders them un-
Figure 4. Adoptive transfer of bm1 or bm12 DLI-treated B6/lpr lym-
phocytes enhances bm1 or bm12 skin graft survival. (A) The spleen and
lymph node cells were collected from B6/lpr mice that were injected in-
travenously with bm1 lymphocytes. B6 /  mice were either left untreated
as a control (  and  , n   10) or injected with 4   107 bm1 DLI-treated
B6/lpr lymphocytes per mouse (  and  , n   8) 1 d before transplanta-
tion. All recipient mice were then given tail skin grafts from both bm1
(solid lines) and BALB/c (dashed lines) donors. bm1 skin graft survival
was significantly prolonged in mice that received lpr lymphocytes when
compared with untreated controls (P   0.05). (B) DNTC were purified
from B6/lpr mice that had been infused with bm1 cells. Naive B6 / 
mice were either left untreated as a control (  and  , n   10) or injected
intravenously with 1.5   107 bm1 DLI-treated B6/lpr DNTC per mouse
(  and  , n   10) 1 d before transplantation. Each mouse was trans-
planted with bm1 (solid lines) and BALB/c (dashed lines) skin grafts. bm1
skin graft survival was significantly prolonged in mice that received lpr
DNTC when compared with untreated controls (P   0.017). (C) DNTC
were purified from B6/lpr mice that had been infused with bm12 cells.
Naive B6 /  mice were injected intravenously with 8.5   106 DNTC ( 
and  , n   7) 1 d before transplantation, or were left untreated as con-
trols (  and  , n   5). Each mouse was transplanted with bm12 (solid
lines) and (B6Xdm2)F1 (dashed lines) skin grafts. bm12 skin graft survival
was significantly prolonged in mice that received lpr DNTC when com-
pared with untreated controls (P   0.0012).266 The Immune Regulatory Function of lpr DN T Cells
susceptible to DNTC-mediated regulation. Our data help
explain the impaired peripheral clonal deletion observed in
Fas null mice (17) and suggest that in addition to regulatory
cells, defects in the target cells that are being regulated may
lead to the development of autoimmune diseases.
Lpr DNTC-mediated regulation is similar to that previ-
ously observed in Ld-specific DNTC T regulatory clones
(11). Both cell types are able to kill syngeneic cells in vitro
using a Fas-dependent mechanism. However, the DNTC
clones generated from 2C transgenic mice only killed syn-
geneic CD8  T cell targets that were activated by the same
antigen (11), whereas primary activated lpr DNTC were
able to kill syngeneic T cells that were activated by either
the same or a different antigen in vitro. This finding is sim-
ilar to that found using some subsets of primary activated
CD4 CD25  T regulatory cells (20, 27), suggesting that
cytotoxicity mediated by primary activated T regulatory
cells is less specific than that mediated by transgenic DNTC
clones. There are many possibilities that might explain the
discrepancy between primary activated lpr DNTC and reg-
ulatory DNTC clone-mediated killing in vitro. First, lpr
DNTC used in these experiments were generated by stim-
ulation with fully allogeneic splenocytes, whereas DNTC
clones were generated from T cells that carry TCR reactive
to only one specific epitope of the Ld antigen. Thus, there
is a higher possibility for TCR-MHC cross-reaction with
the H-2d–specific lpr DNTC compared with single class I
locus (Ld)-specific DNTC clones. Second, nonspecific cy-
totoxicity may result from high expression of FasL on lpr
DNTC. Up-regulation of FasL on effector cells has been
shown to induce nonspecific target cell death, termed by-
stander killing (28). It is known that lpr DNTC constitu-
tively express a higher level of FasL mRNA compared with
non-lpr mice (15). Primary activation in vitro with alloge-
neic cells and cytokines may induce overexpression of FasL
on lpr DNTC resulting in bystander killing. In addition, in
a recent study we have shown that the TCR on both
DNTC and target T cells can influence non-lpr DNTC-
mediated killing (unpublished data) and that in vitro anti-
gen-specific killing can take place in many more conditions
than was initially described using transgenic regulatory
DNTC clones (11). Regardless of the in vitro discrepancy
in antigen specificity, both regulatory DNTC clones (11)
and lpr DNTC are able to suppress immune responses in an
antigen-specific fashion in vivo. As seen in the DNTC
clones, adoptive transfer of in vivo–activated lpr DNTC
into wild-type syngeneic mice enhances donor-specific al-
logeneic skin graft survival. Additional studies are needed
in order to understand what mechanism is responsible for
the discrepancy between the functions of in vitro– and in
vivo–activated lpr DNTC.
Although the ability of DNTC to inhibit allogeneic im-
mune responses mediated by wild-type syngeneic CD4 
and CD8  T cells was clearly demonstrated in this paper, it
is not yet clear whether DNTC can also down-regulate
syngeneic autoreactive T cells. The inability to identify the
self-antigens that cause autoimmune disease in lpr mice
makes it difficult to directly test the ability of lpr DNTC to
suppress autoreactive T cells and prevent autoimmune dis-
ease in these mice. More investigations into the mechanism
and specificity of both regulatory cells and their targets will
lead to a better understanding of the development of au-
toimmune disease.
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